Shots: The company received DCGI’s MA for Teriparatide (biosimilar) for the treatment of Osteoporosis vs anti-resorptive therapies such as bisphosphates and SERMs The approved product will be marketed through Alkem […]readmore
Tags : Teriparatide Biosimilar
Shots: Mochida launched “Teriparatide BS subcutaneous injection Kit 600μg MOCHIDA” as it has been listed on the NIH reimbursement price list The launch will improve QoL and lead to the […]readmore
Shots: Teriparatide biosimilar is the first product developed under Mochida and Gedeon Richter license agreement and is expected to improve the QoL while reducing the financial burden of patients with […]readmore